TOP STORIES

• REGULATORY LDP Health Policy Clique Set to Urge Govt to Skip Off-Year Re-Pricing Next Year, but Explore Middle Ground at Same Time
  November 27, 2020

• REGULATORY MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
  November 26, 2020

• REGULATORY 3 Pharma Groups: Limit Scope of Off-Year Re-Pricing to Drugs with “Significantly Large Discrepancy Rates”
  November 26, 2020

• REGULATORY MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
  November 26, 2020

• REGULATORY Ryukaikon Confab Held after 17 Month Hiatus, COVID-19 Impact on Drug Distribution Discussed
  November 25, 2020

• ACADEMIA Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL
  November 25, 2020

• BUSINESS Improved Hygiene amid COVID-19 Hit Infectious Disease Meds, Big-Seller Hopefuls See Slow Uptake
  November 24, 2020

• REGULATORY 1st Humira Biosimilar to Join NHI Price List on Nov. 25
  November 24, 2020

• BUSINESS Big 3 Generic Makers Log 7.2% Growth in 1st Half, Suffer Sluggish Japan Sales on Price Cuts, COVID-19: Jiho Tally
  November 20, 2020

• ORGANIZATION EFPIA Japan Chief Frets Declining Priority for Japan Market since 2018 Pricing Overhaul
  November 19, 2020

• ACADEMIA National Cancer Center Exploring Effectiveness of Frontline Use of Multigene Panel Testing for Solid Tumors
  November 18, 2020

• REGULATORY Drug Makers Disclosing as Much Cost Info as Possible in Price Negotiations, JPMA Chief Rebuts Concerns Aired in Project Review
  November 17, 2020

• REGULATORY With Consensus on 13 Topics Delayed by COVID-19, ICH Expected to Restrict Selection of New Topics at Virtual Assembly
  November 16, 2020

• REGULATORY “No Comment with Prejudgment” on COVID-19 Shots for Children: Minister
  November 16, 2020

• BUSINESS Generic Makers Seeking to Invalidate Feburic Patent, Can They Get Full Indications?
  November 13, 2020

• BUSINESS New BMS to Rev Up Open Innovation Drive in Japan, Evolve Portfolio in 6 Focus Areas: Country CEO
  November 12, 2020

• REGULATORY Oral Semaglutide, Gilead JAK Inhibitor, Takeda’s PARP Med OK’ed for Listing on Nov. 18
  November 11, 2020

• BUSINESS Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals
  November 11, 2020

• BUSINESS Incyte Gearing Up for Solo Marketing in Japan, Set to Double Workforce to 70 Staffers
  November 10, 2020

• REGULATORY Japan to Set New Technical Fee for CureApp’s Quit Smoking App
  November 10, 2020

ページ

• « 先頭
• ‹ Prev
• …
• 104
• 105
• 106
• 107
• 108
• 109
• 110
• 111
• 112
• …
• Next ›
• 最終 »